Merck Sharp & Dohme LLC

Santa Monica, California

OncologyADCPhase IIIListed · MRK

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

yesterdayTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE1/PHASE2 registered
Jul 2, 2026
Malignant Neoplasm · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
ClinicalTrials.gov · NCT07630974 (opens the source filing in a new tab)
Trial
PHASE2/PHASE3 registered
Jun 22, 2026
Follicular Lymphoma · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
ClinicalTrials.gov · NCT07634471 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jun 18, 2026
Malignant Neoplasm · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
ClinicalTrials.gov · NCT07600749 (opens the source filing in a new tab)
Trial
PHASE1 registered
May 11, 2026
Healthy · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
ClinicalTrials.gov · NCT07548606 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Apr 30, 2026
Lung Neoplasm Malignant · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
ClinicalTrials.gov · NCT07286149 (opens the source filing in a new tab)
Trial
PHASE3 registered
Apr 23, 2026
Bladder Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
ClinicalTrials.gov · NCT07419295 (opens the source filing in a new tab)
Trial
PHASE3 registered
Apr 9, 2026
Carcinoma, Renal Cell · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
ClinicalTrials.gov · NCT07489495 (opens the source filing in a new tab)
Trial
PHASE3 registered
Mar 23, 2026
Von Hippel-Lindau Disease, Malignant Neoplasms · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
ClinicalTrials.gov · NCT07405164 (opens the source filing in a new tab)
Trial
PHASE3 registered
Feb 16, 2026
Ovarian Neoplasms, Ovarian Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
ClinicalTrials.gov · NCT07318558 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Feb 9, 2026
Bladder Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
ClinicalTrials.gov · NCT07232602 (opens the source filing in a new tab)
Trial
PHASE1 registered
Dec 16, 2025
Malignant Neoplasm · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
ClinicalTrials.gov · NCT07247110 (opens the source filing in a new tab)
Trial
PHASE2 registered
Aug 11, 2025
Malignant Neoplasm · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
ClinicalTrials.gov · NCT06979596 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jul 23, 2025
Metastatic Neoplasm · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
ClinicalTrials.gov · NCT07030712 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Jul 3, 2025
Castration-Resistant Prostatic Cancer, Metastasis · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
ClinicalTrials.gov · NCT06863272 (opens the source filing in a new tab)
Trial
PHASE2 registered
Apr 11, 2025
Lymphoma, Large B-Cell, Diffuse · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
ClinicalTrials.gov · NCT06890884 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 30, 2025
Non-small Cell Lung Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
ClinicalTrials.gov · NCT06731907 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 20, 2025
Breast Neoplasms, Breast Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
ClinicalTrials.gov · NCT06797635 (opens the source filing in a new tab)
Trial
PHASE3 registered
Mar 16, 2025
Triple Negative Breast Neoplasms · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
ClinicalTrials.gov · NCT06841354 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 11, 2025
Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
ClinicalTrials.gov · NCT06833073 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jan 27, 2025
Diffuse Large B-Cell Lymphoma · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
ClinicalTrials.gov · NCT06717347 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 27, 2024
Metastatic Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
ClinicalTrials.gov · NCT06428396 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Nov 3, 2024
Gastrointestinal Cancer · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
ClinicalTrials.gov · NCT06596694 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Aug 16, 2024
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
ClinicalTrials.gov · NCT06395103 (opens the source filing in a new tab)
Trial
PHASE3 registered
Dec 13, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
ClinicalTrials.gov · NCT06136559 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 12, 2023
Non-small Cell Lung Cancer (NSCLC) · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
ClinicalTrials.gov · NCT06074588 (opens the source filing in a new tab)
Trial
PHASE1 registered
Oct 26, 2023
Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2) · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
ClinicalTrials.gov · NCT06049212 (opens the source filing in a new tab)
Trial
PHASE2/PHASE3 registered
Jan 14, 2022
DLBCL, Diffuse Large B-Cell Lymphoma · RECRUITING · sponsor: Merck Sharp & Dohme LLC · A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
ClinicalTrials.gov · NCT05139017 (opens the source filing in a new tab)
Trial
PHASE1 registered
Sep 26, 2021
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia · TERMINATED · sponsor: Merck Sharp & Dohme LLC · A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
ClinicalTrials.gov · NCT05038800 (opens the source filing in a new tab)
Trial
PHASE2 registered
Aug 18, 2021
Neoplasm Malignant · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
ClinicalTrials.gov · NCT04976634 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jun 14, 2021
Carcinoma, Renal Cell · COMPLETED · sponsor: Merck Sharp & Dohme LLC · A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
ClinicalTrials.gov · NCT04846920 (opens the source filing in a new tab)
Trial
PHASE2 registered
Apr 5, 2021
Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia · RECRUITING · sponsor: Merck Sharp & Dohme LLC · Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
ClinicalTrials.gov · NCT04728893 (opens the source filing in a new tab)
Trial
PHASE2 registered
Dec 12, 2018
Advanced Solid Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Merck Sharp & Dohme LLC · Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
ClinicalTrials.gov · NCT03742895 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 76%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 1.00name similarity 100% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the trial record at 0.98name similarity 100% · semantic similarity 84% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.96name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
yesterdayTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
yesterdayTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
yesterdayTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
2d agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
2d agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
2w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
2w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
3w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
3w agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
4w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
4w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
5w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
5w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
6w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
6w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
7w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
7w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
8w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
8w agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
8w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
8w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
May 2025Trial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Apr 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE1/PHASE2 registered

PHASE2/PHASE3 registered

PHASE1 registered

PHASE1 registered

PHASE1/PHASE2 registered

PHASE3 registered

PHASE3 registered

PHASE3 registered

PHASE3 registered

PHASE1/PHASE2 registered

PHASE1 registered

PHASE2 registered

PHASE1 registered

PHASE1/PHASE2 registered

PHASE2 registered

PHASE2 registered

PHASE2 registered

PHASE3 registered

PHASE2 registered

PHASE3 registered

PHASE2 registered

PHASE1/PHASE2 registered

PHASE1/PHASE2 registered

PHASE3 registered

PHASE3 registered

PHASE1 registered

PHASE2/PHASE3 registered

PHASE1 registered

PHASE2 registered

PHASE1 registered

PHASE2 registered

PHASE2 registered